KLRA Kailera Therapeutics, Inc.
Company Analysis
Latest News
🟢 Kailera Therapeutics is trading 5% up today amid a broad biotech-sector rally
Kailera Therapeutics is trading 5.26% up now at $17.41, primarily benefiting from a broad biotech-sector rally rather than a confirmed company-specific...
Kailera Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 25, 2026
For the second quarter of 2026, analysts anticipate Kailera Therapeutics will report a consensus net loss of $0.74 per share on zero revenue, with the stock...
🟢 Kailera Therapeutics is trading 4.01% up in pre-market amid firmer Nasdaq futures, no fresh company catalyst
Kailera Therapeutics is trading at $18.16, up 4.01% in pre-market on August 21, 2026, primarily amid stronger broader risk sentiment. - Nasdaq Composite...
🔴 Kailera Therapeutics falls 4.3% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🔴 Kailera Therapeutics is trading 4% down today amid biotechnology sector weakness
Kailera Therapeutics is trading 4.02% down now at $17.77 as biotechnology shares weaken and broader risk appetite fades. - The biotechnology sector fell 4.03%...
🟢 Kailera Therapeutics is trading 8.1% up in pre-market after August 12 report details obesity-pipeline progress
Kailera Therapeutics is trading at $20.01 (+8.1%) in pre-market after its August 12, 2026 second-quarter report outlined obesity-pipeline progress. • The...
🟢 Kailera Therapeutics is trading 4% up today after its second-quarter report
Kailera Therapeutics is trading 4.01% up at $18.66 as investors continue digesting its August 12, 2026 second-quarter report and business updates. - Reported...
RTW Investments takes 8.3% stake in Kailera, backing obesity drug developer
RTW Investments disclosed an 8.3% passive stake in Kailera Therapeutics, Inc. The healthcare investment firm reported the position in a Schedule 13G filing...
Kailera Rallied on Its Obesity Pipeline — But Can a Pre-Revenue Biotech Burning $111 Million a Quarter Justify the Bet?
Shares shifted as Kailera Therapeutics jumped 6.9% to $19.88 the morning after its second-quarter report landed a mix of ugly losses and promising drug...
🟢 Kailera Therapeutics is trading 6.94% up in pre-market after progress toward global Phase 3 obesity trials
Kailera Therapeutics is trading 6.94% up now in pre-market at $19.88 after its August 12, 2026, second-quarter report highlighted progress toward global Phase...
Kailera Therapeutics second quarter 2026 net loss widens to $111M while obesity pipeline advances
Kailera Therapeutics reported a significant expansion in net loss for the second quarter of 2026, primarily driven by a 418% year-over-year increase in...
🟢 Kailera Therapeutics is trading 5.94% up in pre-market after announcing CTO appointment
Kailera Therapeutics is trading 5.94% up in pre-market at $19.99 after announcing Nur Nicholson as chief technology officer on August 11, 2026, effective...
🟢 Kailera Therapeutics is trading 6.06% up in pre-market possibly ahead of August 12 earnings
Kailera Therapeutics is trading 6.06% up at $19.79 in pre-market, with positioning ahead of its August 12 second-quarter 2026 earnings a possible factor. -...
🟢 Kailera Therapeutics is trading 4.3% up today amid a broad biotech and market rally
Kailera Therapeutics is trading 4.3% up at $18.06 as the stock participates in a broad risk-on move in U.S. equities and a rally among biotechnology peers. •...
🔴 Kailera Therapeutics is trading 5.4% down today as investors reassess high-beta obesity stocks amid macro caution
Kailera Therapeutics is trading at $16.39 (5.4% down) as the stock retraces a portion of its previous 15% surge amid a shift toward a more cautious...
🟢 Kailera Therapeutics is trading 15% up today amid broad risk-on sentiment and index gains
Kailera Therapeutics is trading at $19.91 (15%) up in after-hours sessions, extending its earlier pre-market strength amid a broad risk-on tone and strong...
🟢 Kailera Therapeutics is trading 6% up today amid broader market strength and risk-on sentiment
Kailera Therapeutics is trading 6% up at $17.95 in pre-market as the move appears tied to an improving risk-on tone in U.S. equity futures and broader market...
🟢 Kailera Therapeutics is trading 6.2% up today on a relief rebound following biotech sector weakness
Kailera Therapeutics is trading 6.2% up today at $17.78 as the stock stages a relief rebound from a recent sector-driven slide. • The move follows a 4.4% drop...
🔴 Kailera Therapeutics is trading 4.4% down today on broader biotech sector weakness
Kailera Therapeutics is trading 4.4% down at $16.00 in after-hours trading, extending a recent multi-day slide amid broader biotech sector weakness. • The...
🔴 Kailera Therapeutics falls 4.2% — Biotech Stocks Decline on Broad Market Weakness
With Biotech (XBI) down 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...